Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project.

Willemse EAJ, van Maurik IS, Tijms BM, Bouwman FH, Franke A, Hubeek I, Boelaarts L, Claus JJ, Korf ESC, van Marum RJ, Roks G, Schoonenboom N, Verwey N, Zwan MD, Wahl S, van der Flier WM, Teunissen CE.

Alzheimers Dement (Amst). 2018 Sep 12;10:563-572. doi: 10.1016/j.dadm.2018.08.006. eCollection 2018.

2.

Hippocampal Calcifications: Risk Factors and Association with Cognitive Function.

de Brouwer EJM, Kockelkoren R, Claus JJ, de Jonghe A, Geerlings MI, Jongsma TEF, Mali WPTM, Hendrikse J, de Jong PA, Koek HL.

Radiology. 2018 Sep;288(3):815-820. doi: 10.1148/radiol.2018172588. Epub 2018 Jun 12.

PMID:
29893650
3.

Cerebral White Matter Lesions have Low Impact on Cognitive Function in a Large Elderly Memory Clinic Population.

Claus JJ, Coenen M, Staekenborg SS, Schuur J, Tielkes CEM, Koster P, Scheltens P.

J Alzheimers Dis. 2018;63(3):1129-1139. doi: 10.3233/JAD-171111.

PMID:
29710708
4.

Patients' and caregivers' views on conversations and shared decision making in diagnostic testing for Alzheimer's disease: The ABIDE project.

Kunneman M, Pel-Littel R, Bouwman FH, Gillissen F, Schoonenboom NSM, Claus JJ, van der Flier WM, Smets EMA.

Alzheimers Dement (N Y). 2017 May 10;3(3):314-322. doi: 10.1016/j.trci.2017.04.002. eCollection 2017 Sep.

5.

Practical use of visual medial temporal lobe atrophy cut-off scores in Alzheimer's disease: Validation in a large memory clinic population.

Claus JJ, Staekenborg SS, Holl DC, Roorda JJ, Schuur J, Koster P, Tielkes CEM, Scheltens P.

Eur Radiol. 2017 Aug;27(8):3147-3155. doi: 10.1007/s00330-016-4726-3. Epub 2017 Jan 12.

6.

Low Prevalence of Mixed Dementia in a Cohort of 2,000 Elderly Patients in a Memory Clinic Setting.

Claus JJ, Staekenborg SS, Roorda JJ, Stevens M, Herderschee D, van Maarschalkerweerd W, Schuurmans L, Tielkes CE, Koster P, Bavinck C, Scheltens P.

J Alzheimers Dis. 2016;50(3):797-806. doi: 10.3233/JAD-150796.

PMID:
26757192
7.

Determinants of quantitative spectral electroencephalography in early Alzheimer's disease: cognitive function, regional cerebral blood flow, and computed tomography.

Claus JJ, Ongerboer De Visser BW, Bour LJ, Walstra GJ, Hijdra A, Verbeeten B Jr, Van Royen EA, Kwa VI, van Gool WA.

Dement Geriatr Cogn Disord. 2000 Mar-Apr;11(2):81-9.

PMID:
10705165
8.

The diagnostic value of electroencephalography in mild senile Alzheimer's disease.

Claus JJ, Strijers RL, Jonkman EJ, Ongerboer de Visser BW, Jonker C, Walstra GJ, Scheltens P, van Gool WA.

Clin Neurophysiol. 1999 May;110(5):825-32.

PMID:
10400195
9.

A simple test of copying ability and sex define survival in patients with early Alzheimer's disease.

Claus JJ, Walstra GJ, Bossuyt PM, Teunisse S, Van Gool WA.

Psychol Med. 1999 Mar;29(2):485-9.

PMID:
10218940
10.
11.

Slowing on quantitative spectral EEG is a marker for rate of subsequent cognitive and functional decline in early Alzheimer disease.

Claus JJ, Kwa VI, Teunisse S, Walstra GJ, van Gool WA, Koelman JH, Bour LJ, Ongerboer de Visser BW.

Alzheimer Dis Assoc Disord. 1998 Sep;12(3):167-74.

PMID:
9772019
12.

Electroencephalography and survival in patients with Alzheimer's disease.

Claus JJ, Bour LJ, Ongerboer de Visser BW.

Neurology. 1998 Sep;51(3):918-9. No abstract available.

PMID:
9748068
13.

Quantitative spectral electroencephalography in predicting survival in patients with early Alzheimer disease.

Claus JJ, Ongerboer de Visser BW, Walstra GJ, Hijdra A, Verbeeten B Jr, van Gool WA.

Arch Neurol. 1998 Aug;55(8):1105-11.

PMID:
9708961
14.

Predicting survival in patients with early Alzheimer's disease.

Claus JJ, van Gool WA, Teunisse S, Walstra GJ, Kwa VI, Hijdra A, Verbeeten B Jr, Koelman JH, Bour LJ, Ongerboer De Visser BW.

Dement Geriatr Cogn Disord. 1998 Sep-Oct;9(5):284-93.

PMID:
9701680
15.

Reversible blindness in AIDS-related cryptococcal meningitis.

Claus JJ, Portegies P.

Clin Neurol Neurosurg. 1998 Mar;100(1):51-2.

PMID:
9637206
16.

Registration of MR and SPECT without using external fiducial markers.

de Munck JC, Verster FC, Dubois EA, Habraken JB, Boltjes B, Claus JJ, van Herk M.

Phys Med Biol. 1998 May;43(5):1255-69.

PMID:
9623654
17.

Determinants of global clinical change assessment in patients with early Alzheimer's disease.

Claus JJ, Teunisse S, Walstra GJ, van Gool WA.

Dement Geriatr Cogn Disord. 1998 May-Jun;9(3):157-63.

PMID:
9622004
18.

Lisuride treatment of Alzheimer's disease. A preliminary placebo-controlled clinical trial of safety and therapeutic efficacy.

Claus JJ, de Koning I, van Harskamp F, Breteler MM, Voet B, Gutzmann H, Dahlke F, van der Cammen T, Hofman A.

Clin Neuropharmacol. 1998 May-Jun;21(3):190-5.

PMID:
9617511
19.

Regional cerebral blood flow and cerebrovascular risk factors in the elderly population.

Claus JJ, Breteler MM, Hasan D, Krenning EP, Bots ML, Grobbee DE, Van Swieten JC, Van Harskamp F, Hofman A.

Neurobiol Aging. 1998 Jan-Feb;19(1):57-64.

PMID:
9562504
20.

Demonstration of a reduction in muscarinic receptor binding in early Alzheimer's disease using iodine-123 dexetimide single-photon emission tomography.

Claus JJ, Dubois EA, Booij J, Habraken J, de Munck JC, van Herk M, Verbeeten B Jr, van Royen EA.

Eur J Nucl Med. 1997 Jun;24(6):602-8.

PMID:
9169565
21.

SPECT in AD.

Claus JJ, van Gool WA, Feldman H, Mohr E.

Neurology. 1997 Apr;48(4):1139-40. No abstract available.

PMID:
9109925
22.

Basal ganglia disease and visuospatial cognition: Are there disease-specific impairments?

Mohr E, Claus JJ, Brouwers P.

Behav Neurol. 1997;10(2):67-75. doi: 10.3233/BEN-1997-102-304.

23.

Clinicopathological studies of Alzheimer disease.

Claus JJ.

Arch Neurol. 1996 Sep;53(9):837. No abstract available.

PMID:
8815846
24.

Vascular risk factors, atherosclerosis, cerebral white matter lesions and cerebral perfusion in a population-based study.

Claus JJ, Breteler MM, Hasan D, Krenning EP, Bots ML, Grobbee DE, van Swieten JC, van Harskamp F, Hofman A.

Eur J Nucl Med. 1996 Jun;23(6):675-82.

PMID:
8662102
25.

Attentional deficits in Alzheimer's, Parkinson's, and Huntington's diseases.

Claus JJ, Mohr E.

Acta Neurol Scand. 1996 May;93(5):346-51.

PMID:
8800345
26.

A novel approach to the determination and characterization of HIV dementia.

Brouwers P, Mohr E, Hildebrand K, Hendricks M, Claus JJ, Baron IS, Young M, Pierce P.

Can J Neurol Sci. 1996 May;23(2):104-9.

PMID:
8738921
27.

[Listeria meningitis in adults].

Claus JJ, Kuijper EJ, de Gans J.

Ned Tijdschr Geneeskd. 1996 Jan 20;140(3):113-6. Dutch. No abstract available.

PMID:
8618625
28.

Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study.

Ott A, Breteler MM, van Harskamp F, Claus JJ, van der Cammen TJ, Grobbee DE, Hofman A.

BMJ. 1995 Apr 15;310(6985):970-3.

29.

Differential classification of dementia.

Mohr E, Brouwers P, Claus JJ, Purdon SE, Gagnon M, Chase TN.

Behav Neurol. 1995;8(1):23-30. doi: 10.3233/BEN-1995-8103.

30.

Assessment of cerebral perfusion with single-photon emission tomography in normal subjects and in patients with Alzheimer's disease: effects of region of interest selection.

Claus JJ, van Harskamp F, Breteler MM, Krenning EP, van der Cammen TJ, Hofman A, Hasan D.

Eur J Nucl Med. 1994 Oct;21(10):1044-51.

PMID:
7828613
31.

Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: the Rotterdam Study.

Breteler MM, van Swieten JC, Bots ML, Grobbee DE, Claus JJ, van den Hout JH, van Harskamp F, Tanghe HL, de Jong PT, van Gijn J, et al.

Neurology. 1994 Jul;44(7):1246-52.

PMID:
8035924
32.

Cardiovascular disease and distribution of cognitive function in elderly people: the Rotterdam Study.

Breteler MM, Claus JJ, Grobbee DE, Hofman A.

BMJ. 1994 Jun 18;308(6944):1604-8.

33.

Cognitive correlates of ventricular enlargement and cerebral white matter lesions on magnetic resonance imaging. The Rotterdam Study.

Breteler MM, van Amerongen NM, van Swieten JC, Claus JJ, Grobbee DE, van Gijn J, Hofman A, van Harskamp F.

Stroke. 1994 Jun;25(6):1109-15.

PMID:
8202966
34.

The diagnostic value of SPECT with Tc 99m HMPAO in Alzheimer's disease: a population-based study.

Claus JJ, van Harskamp F, Breteler MM, Krenning EP, de Koning I, van der Cammen TJ, Hofman A, Hasan D.

Neurology. 1994 Mar;44(3 Pt 1):454-61.

PMID:
8145915
35.

[Pharmacological therapy of Alzheimer's disease].

Claus JJ, Hofman A, Jolles J.

Ned Tijdschr Geneeskd. 1992 Dec 12;136(50):2463-6. Review. Dutch. No abstract available.

PMID:
1465168
36.

Epidemiology of Alzheimer's disease.

Breteler MM, Claus JJ, van Duijn CM, Launer LJ, Hofman A.

Epidemiol Rev. 1992;14:59-82. Review. No abstract available.

PMID:
1289117
37.

Nootropic drugs in Alzheimer's disease: symptomatic treatment with pramiracetam.

Claus JJ, Ludwig C, Mohr E, Giuffra M, Blin J, Chase TN.

Neurology. 1991 Apr;41(4):570-4.

PMID:
2011259
38.

Clinical trials in dementia: learning effects with repeated testing.

Claus JJ, Mohr E, Chase TN.

J Psychiatry Neurosci. 1991 Mar;16(1):1-4.

39.

Visuospatial cognition in Huntington's disease.

Mohr E, Brouwers P, Claus JJ, Mann UM, Fedio P, Chase TN.

Mov Disord. 1991;6(2):127-32.

PMID:
1829137
40.

Clonidine treatment of Alzheimer's disease.

Mohr E, Schlegel J, Fabbrini G, Williams J, Mouradian MM, Mann UM, Claus JJ, Fedio P, Chase TN.

Arch Neurol. 1989 Apr;46(4):376-8.

PMID:
2650662

Supplemental Content

Loading ...
Support Center